Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Stryker has been in a holding pattern, posting a small return of 1.1% while floating around $376.76. Is now the time to buy ...

Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $3,978.93 today based on a ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other best medical ...

Investors in Stryker Corp (Symbol: SYK) saw new options become available today, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK ...

Looking at stock returns, SYK, with 0% returns in the last twelve months, has fared better than ISRG stock, down 20%, and the broader S&P500 index, down 9%.

Investors in Stryker Corp (Symbol: SYK) saw new options begin trading today, for the September 2026 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Spleen tyrosine kinase (SYK) is known to have a crucial role in adaptive immune receptor signalling. However, recent reports indicate that SYK also mediates other, unexpectedly diverse biological ...